To examine whether DDX54 promoted CRC progression through p65 and AKT pathway, the CRC cells were treated with Bortezomib (Btz, p-p65 inhibitors) and MK-2206 (AKT inhibitors) respectively. Here, AKT1 is linked to colorectal carcinoma.